Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies
Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and
bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is …
bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is …
Thrombopoiesis‐stimulating agents and myelodysplastic syndromes
CK Brierley, DP Steensma - British journal of haematology, 2015 - Wiley Online Library
Thrombocytopenia in patients with myelodysplastic syndromes (MDS) is a frequent cause of
haemorrhage‐related morbidity and mortality, and is associated with increased risk of …
haemorrhage‐related morbidity and mortality, and is associated with increased risk of …
[HTML][HTML] Thrombocytopenia in patients with myelodysplastic syndromes: still an unsolved problem
M Basood, HS Oster, M Mittelman - Mediterranean journal of …, 2018 - ncbi.nlm.nih.gov
Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia
J Waisbren, S Dinner, J Altman, O Frankfurt… - International journal of …, 2017 - Springer
Patients with myelodysplastic syndrome (MDS) who present with isolated thrombocytopenia
(TCP) constitute a poorly described subgroup. The aim of the present study was to …
(TCP) constitute a poorly described subgroup. The aim of the present study was to …
Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents
S Vadhan-Raj - Seminars in hematology, 2009 - Elsevier
Myelosuppression, one of the most common toxicities of chemotherapy, results in varying
degree of cytopenias. While neutropenia and anemia have been reduced with the currently …
degree of cytopenias. While neutropenia and anemia have been reduced with the currently …
Thrombocytopenia in patients with myelodysplastic syndromes
J Bryan, E Jabbour, H Prescott, H Kantarjian - Seminars in hematology, 2010 - Elsevier
Thrombocytopenia, common in leukemias and myelodysplastic syndromes (MDS), is
responsible for increased risk of bleeding and delay of therapy. Platelet transfusions …
responsible for increased risk of bleeding and delay of therapy. Platelet transfusions …
[HTML][HTML] Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a …
Abstract Abstract 923 Introduction: The increased risk of bleeding in myelodysplastic
syndromes (MDS) is due to low platelet (PLT) counts and abnormalities of PLT morphology …
syndromes (MDS) is due to low platelet (PLT) counts and abnormalities of PLT morphology …
Safety and efficacy of thrombopoietin‐receptor agonists in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials
A Prica, M Sholzberg… - British journal of …, 2014 - Wiley Online Library
Summary Thrombocytopenia is common (40–65%) and potentially serious in
myelodysplastic syndromes (MDS). A systematic review was conducted to determine the …
myelodysplastic syndromes (MDS). A systematic review was conducted to determine the …
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
P Fenaux, P Muus, H Kantarjian… - British journal of …, 2017 - Wiley Online Library
Romiplostim can improve platelet counts in about 50% of patients with low‐or intermediate 1‐
risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long‐term …
risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long‐term …
[HTML][HTML] Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: results of the 8-week open-label part of an …
M Mittelman, S Assouline, E Briasoulis, A Alonso… - Blood, 2012 - Elsevier
Abstract Abstract 3822 Background: Patients with myelodysplastic syndromes (MDS) or
acute myeloid leukemia (AML) commonly experience severe thrombocytopenia with a high …
acute myeloid leukemia (AML) commonly experience severe thrombocytopenia with a high …